Complacency over COVID-19 despite new wave

Follow us on Google News:

Almost two-thirds of Australians believe the worst of the COVID-19 pandemic is behind them despite a new wave of infections and different variants of the virus emerging, research by Pfizer suggests.

One in three people is less likely to get tested when they have symptoms now compared with a year ago.

The findings have prompted stark warnings from health professionals. 

University of Sydney infectious diseases specialist Professor Robert Booy said the apparent decline in testing was a major concern and urged Australians to keep up to date with their vaccinations. 

"Recent federal government data has shown COVID-19 still poses a very real risk to the health of our communities as we move into a new wave of infections, specifically to those at higher risk of serious illness," Prof Booy said.

"Testing earlier means people can seek medical advice sooner and can access anti-viral medicines faster if they are eligible." 

Almost two-thirds of Australians are also less concerned about how COVID-19 is affecting their community, while about half aren't as worried about their own risk of serious illness.

One in five people who are at higher risk, such as those over 70 or with health conditions including heart disease, are less likely to get tested or see a doctor if they experience symptoms.

The research findings are based on a November survey of 1000 Australian adults by Pfizer Australia.

Higher-risk people are more likely to be severely ill and hospitalised because of COVID-19, so it's important they act fast and speak to their general practitioner if they test positive, Hearts4heart founder Tanya Hall said.

Australians who are reinfected after previously being hospitalised could soon have greater access to government subsidised antivirals.

This week an advisory board recommended the Pharmaceutical Benefit Scheme lower it's threshold from only those that are considered high risk of developing severe illness.

Following its November meeting, the Pharmaceutical Benefits Advisory Committee recommended the changes apply to antivirals, molnupiravir and nirmatrelvir and ritonavir.

If the changes are adopted eligible patients will be able to access the medicines from a pharmacy after returning a positive test and getting a prescription from their doctor.

Cases of the virus are continually on the rise in Australia, with a daily average of almost 10,800 cases as of the week ending November 15 - an increase of about 38 per cent on the previous week.

It is estimated 9800 Australians died from COVID-19 in the first 10 months of 2022, making it the third-leading cause of death between January and October, according to the Actuaries Institute. 

Australian authorities are closely monitoring a second Omicron variant's transmission overseas, and all indications are that a new COVID-19 wave has started in the country, Chief Medical Officer Paul Kelly has said. 

In NSW, case numbers are rising at a slower rate than in previous weeks, which is consistent with the national trend.

Deaths reported in the past week fell in NSW but increased by 50 per cent in Victoria.


* NSW: 31,531 cases, 25 deaths

* Victoria: 22,281 cases, 68 deaths

* Queensland: 10,082 cases, 14 deaths

* Western Australia: 10,520 cases, 15 deaths

* South Australia: 9000 cases, 8 deaths

* Tasmania: 2712 cases, no deaths

* Northern Territory: 329 cases, no deaths

* ACT: 1757 cases, no deaths.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Featured Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK